INTRODUCTION
Lung cancer is the most prevalent cancer worldwide and the 5-year survival rate is around 16% (1) . Although many new targeted therapeutic drugs such as gefitinib, erlotinib, and bevacizumab (2-4) have been used for treating lung cancers, cytotoxic drugs such as cisplatin are still used as the first-line treatment (5, 6 ). One of the major problems in improving survival rate of lung cancer patients is the existence of drug resistance in chemotherapy. Platinum resistance has been investigated to a great extent and increased DNA repair is considered as one of the major mechanisms of platinum resistance (7) . While there are several known DNA repair pathways (8) , DNA damages induced by platinum anticancer drugs is primarily repaired by nucleotide excision repair (NER) mechanism (9) . The NER pathway is a complicated multistep process involving multiple proteins including replication protein A (RPA) and xeroderma pimentosum group proteins (e.g., XPA and XPC) (8) . In fact, the increased expression level of these NER proteins has been associated with cisplatin resistance (9) (10) (11) (12) (13) (14) (15) . However, the underling mechanism for their increased expression in cisplatin-resistant cancers is not yet understood.
eIF3 is the most complex translation initiation factor, consisting of 13 putative subunits named as eIF3a-eIF3m (16, 17) . eIF3 plays a critical role in all translation initiation steps. First, it is involved in dissociating the post-termination 80S ribosomes by binding with 40S ribosomal subunit and forming a complex to maintain the 40S ribosomal subunit in a dissociated state and to prevent re-association of free 40S and 60S subunits. Second, eIF3 participates in the 43S pre-initiation complex formation by binding to the 40S ribosome and facilitates recruiting GTP-eIF2-tRNA-methionine ternary complex. Third, eIF3 stimulates mRNA binding with 43S pre-initiation complex. It is also involved in the scanning and recognizing start codon. In addition to the above cap dependent translational process, eIF3 also plays an important role in cap independent translation regulation by binding to the putative internal ribosome entry site (IRES) element (18) . eIF3a, the largest subunit of eIF3 complex, has been shown to play a role in regulating synthesis of proteins including α-tubulin, ribonucleotide reductase M2 and p27 (19, 20) and in cell proliferation (19) , cell cycle control (21) , as well as cell differentiation (22) .
Over-expression of eIF3a has been found in many cancers such as cancers of lung (23) , breast (23) , cervix (24) , stomach (25) and esophagus (26) . eIF3a appeared to be essential for cancer cells to maintain malignant phenotype (19) and ectopic over-expression of eIF3a transformed NIH3T3 cells in vitro (27) . Moreover, it has been observed previously that cervical and esophageal cancer patients with high eIF3a level had better relapse-free and overall survival than that with low eIF3a expression (24, 26) , suggesting that eIF3a may affect patient responses to treatments.
In this study, we tested the hypothesis that eIF3a plays an important role in cisplatin response in lung cancer treatments by regulating the expression of NER proteins. We found that eIF3a expression correlates with response of lung cancer patients to platinum-based chemotherapy. eIF3a knockdown or ectopic over-expression increased and decreased, respectively, cellular resistance to cisplatin and anthrocycline anticancer drugs. Further investigation showed that eIF3a regulates the expression of NER proteins and NER activity case. The score of cells exhibiting staining in each case was evaluated semi quantitatively as previously described (30) . Briefly, a numeric intensity score was set from 1 to 4 with 1 for no; knockdown, H1299 cells were seeded in 6-well plates and transfected with 50 nM eIF3a or scrambled control siRNA using Lipofectamine 2000 as previously described (19, 20) and incubated for 48 hrs followed by cell lysis for further analysis. To establish stable clones with eIF3a over-expression, NIH3T3 cells in 12-well plate were transfected with eIF3a cDNA in pCβA (19, 20) or vector control using Lipofectamine2000 according to manufacturer's instructions. Forty-eight hrs following transfection, cells were collected and replated in 100mm dishes followed by selection with 600 ȝg/ml G418 (Invitrogen, Carlsbad, California, USA) for 2 weeks. The G418 resistant clones were selected and tested for eIF3a expression using Western blot. The positive stable clones were maintained in the presence of 350 ȝg/ml G418.
Survival assay. Chemosensitivity was determined using methyl thiazolyl tetrazlolium (MTT) assay as we described previously (31) . Briefly, cells were seeded in 96-well plates and allowed to grow for 24 hrs followed by incubation with anticancer drugs for 96 hrs. Culture medium was then removed and cells were incubated with 1 mg/ml thiazolyl blue tetrazolium bromide (Sigma) for 4 hrs at 37 o C. The formazan was solubilized in dimethyl sulfoxide and OD 570nm was measured using a Dynex MRX-TC Revelation microplate reader (Chantilly, VA, USA). The IC 50 was obtained from the dose-response curves using GraphPad Prism TM 5.0
program (GraphPad Software, Inc, La Jolla, California, USA).
Real-time RT-PCR.
Real time RT-PCR was performed as previously described (32) .
Briefly, total RNAs were isolated using RNeasy Mini Kit (Qiagen, Maryland, USA) and 1 ȝg of total RNAs were used for reverse transcription using iScript cDNA synthesis kit (Bio-Rad, Hercules, California, USA) according to manufacturer's instructions. Real-time PCR were performed in a 7500 Real-Time PCR System (Applied Biosystems, Foster City, California, USA) using Power SYBR ® Green RNA-to-CT™ 1-Step Kit (Applied Biosystems, Foster City, California, USA) according to manufacturer's instructions. The threshold cycle (C t ) of each reaction was determined and normalized to that of β-actin internal control.
Protein sample preparation and Western Blot analysis. Protein sample preparation
and Western blot analyses were performed as previously described (19, 20, 31) . Briefly, cells were lysed in RIPA lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1% NP-40, 1 mM sodium orthovanadate, 1 mM EDTA, 1mM sodium floride, 100 ȝg/ml PMSF, 100ȝg/ml DTT) at 4°C for 30 mins. The lysates were
clarified by centrifugation at 10,000×g for 10 min at 4 . To prepare nuclear extracts, cells were first lysed in buffer A (10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM PMSF, 1 mM sodium orthovanadate, 6% NP-40) and centrifuged for 5 min at 1,500g. The nuclear pellets were then extracted using RIPA buffer. Protein concentration of the lysate samples was determined using the Bio-Rad Protein Assay kit.
For Western blot analysis, protein samples were separated by SDS-PAGE and transferred to PVDF membranes (Bio-Rad, Hercules, California, USA). The membranes were then blocked with 5% nonfat milk and incubated with primary antibodies overnight followed by washing and reaction with HRP-conjugated secondary antibody. The reaction was detected using ECL reagents (GE Healthcare, Buckinghamshire, UK) and the signals were captured using x-ray films.
Host-cell reactivation assay (HCR).
The firefly luciferase assay-based HCR was performed as previously described (33) . Briefly, the pCMVluc plasmid (50ȝg/ml) in a 24-well plate was UV irradiated on ice using a Stratalinker UV Crosslinker (Stratagene, La Jolla, California, USA). UV-induced damages were verified using PCR (34) with a forward primer 
RESULTS
Correlation of eIF3a expression with chemotherapy response. The eIF3a expression level in cancer tissues of these patients was evaluated using IHC. Fig. 1 shows representative different grade of eIF3a staining in these cancer tissues. eIF3a staining did not appear to have any significant correlation with the clinical characteristics listed in Table S1 .
However, eIF3a staining had significant correlation with chemotherapy responses of SCC (P=0.032), adenocarcinoma (P=0.038) and SCLC (P=0.025) patients although this correlation was not observed with other histological types possibly due to their small sample size (Table 1 and S2 ). In general, chemotherapy responsive patients had higher eIF3a expression in their lung cancers. About 52.1%, 65.6%, and 65.0% of chemotherapy responders of SCC, adenocarcinoma and SCLC patients had high eIF3a level, respectively.
These numbers go down to 47.9%, 34.4% and 35.0% of the non-responders. Similar significant correlation was also observed in total patients with 58.7% of responders and 
enrolled patients received platinum-based chemotherapy as their first line of treatments, we next tested if eIF3a expression affects cisplatin sensitivity using cell lines. For this purpose, we first performed an experiment to knock down eIF3a in human lung cancer cell line H1299 and tested if these cells become more resistant to cisplatin. As shown in Fig. 2A, eIF3a expression was successfully reduced by siRNA as determined using Western blot and realtime RT-PCR analyses. Next, these cells were subjected to MTT assay in the absence or presence of different concentrations of cisplatin. As shown in Fig. 2B , H1299 cells with reduced eIF3a expression are significantly more resistant to cisplatin than the control scramble siRNA-transfected cells with a nearly doubled relative resistance factor.
We next tested if eIF3a knockdown also affects the cellular response to other commonly used anticancer agents including doxorubicin, etoposide, vincristine, and vinblastine. As shown in Fig. 2C , knocking down eIF3a expression significantly increased cellular resistance to doxorubicine and etoposide, but not to vincristine and vinblastine.
Together, these observations suggest that eIF3a expression may influence cellular responses to DNA-damaging anticancer drugs but not to vinca alkaloids.
Effect of eIF3a over-expression on cellular response to anticancer drugs.
To further determine the role of eIF3a expression in cellular response to drug treatments, we established two eIF3a over-expressing stable cell lines using NIH3T3 cells that express low level of endogenous eIF3a (19) . Fig. 3A shows two stable clones that have over-expression of eIF3a at both mRNA and protein levels compared with the vector-transfected control clone.
Next, these cells were subjected to MTT assay following treatments with different concentrations of cisplatin. As shown in Fig. 3B , the stable clones with eIF3a over-expression are significantly more sensitive to cisplatin than the vector-transfected control cells with more than 50% decrease in relative resistance factor. Other anticancer drugs were also tested with these clones. As shown in Fig. 3C , compared to the vector-transfected control clone the stable clones with eIF3a over-expression are significantly more sensitive to doxorubicine and etoposide but not to vincristine and vinblastine. This observation is consistent with the eIF3a knockdown studies (Fig. 2) . Thus, we conclude that eIF3a expression contributes to cellular response to DNA-damaging anticancer drugs but not to vinca alkaloids.
Effect of eIF3a expression on cellular NER activity. The above observation that eIF3a expression contributes to cellular response to DNA-damaging drugs suggest that eIF3a may affect DNA repair activities. To test this hypothesis, we analyzed if altering eIF3a expression affects NER activity which is responsible for repair of DNA damages induced by cisplatin using host cell reactivation (HCR) assay. For this purpose, a plasmid containing luciferase reporter was UV-irradiated to generate DNA adducts which were confirmed using PCR analysis (Fig. 4C) . The damaged reporter plasmids were then transfected into H1299 cells with reduced eIF3a knockdown and NIH3T3 cells with eIF3a over-expression followed by analysis of luciferase activity. As shown in Fig. 4A and 4B, the luciferase activity reduces with the increasing DNA damages due to higher doses of UV irradiation. However, the luciferase activity in H1299 cells with eIF3a knockdown is significantly higher than the control cells transfected with scrambled siRNA (Fig. 4A) . The luciferase activity in NIH3T3 cells with eIF3a over-expression is reduced compared with the control clone (Fig. 4B) . These Effect of eIF3a expression on NER protein level. Previously, it has been shown that eIF3a plays an important role in regulating the translation of a subset of mRNAs including p27 and ribonucleotide reductase M2 (19, 20) . Together with the above findings that eIF3a suppresses cellular NER activity, we propose that eIF3a may regulate the expression of proteins important for NER. To test this possibility, we examined if altering eIF3a level affects the expression of XPA, XPC, Rad23B, RPA, and PCNA, which are important proteins for NER using both H1299 cells with eIF3a knockdown and NIH3T3 cells with eIF3a over-expression. As shown in Fig. 5A and 5C , the protein level of XPA, XPC, RPA14, RPA32, RPA70, and Rad23B were all increased in H1299 cells with eIF3a knockdown compared with the vector-transfected control cells while the protein level of all these proteins in NIH3T3 stable clones with eIF3 over-expression decreased compared with the control clone. However, the protein level of PCNA in these cells was not changed.
To examine if the effect of eIF3a on the expression of NER proteins is at the transcriptional level, we determined the mRNA level of these proteins using real time RT-PCR. As shown in Fig. 5B and 5D , the mRNA level of none of these NER proteins was affected by either reducing eIF3a expression in H1299 cells or over-expressing eIF3a in NIH3T3 cells. Thus, we conclude that likely eIF3a regulates the synthesis of NER proteins XPA, XPC, RPA14, RPA32, RPA70, and Rad23B which, in turn, regulates the NER activity and cellular responses to DNA damages. In this study, we found that eIF3a was highly expressed in responders compared to the non-responders of lung cancer patients to platinum-based chemotherapy. We further demonstrated that eIF3a regulates the expression of DNA repair enzymes which, in turn, contributes to DNA repair activities and cellular response to DNA damages. The eIF3a regulation of DNA repair protein expression is likely at their translational level.
Platinum-derived anticancer drugs have been used to treat many types of cancers including lung, cervical, and esophageal cancers. Unfortunately, resistance to platinum drugs frequently occurs and limits the efficacy of these drugs. The current finding that eIF3a expression correlates with clinical outcome and response to platinum-based chemotherapy of lung cancers and that eIF3a contributes to cellular response to cisplatin indicates that eIF3a may serve as an independent marker predicting patient drug response. Assessing eIF3a level may help design individualized treatment strategies for lung cancer patients. Since cisplatin is also a primary anti-cancer drug for many other cancers, such as cervical and esophageal cancer, it is conceivable that eIF3a may contribute to cisplatin response and serve as an independent prognostic marker predicting drug response and help design individualized treatment strategies for these cancer patients as well. Because eIF3a also appears to affect cellular responses to other DNA-damaging anticancer drugs such as doxorubicin, it is tempting to speculate that eIF3a expression may also contribute response to these anticancer drugs in cancers that are treated with these drugs.
Although we observed the association between eIF3a expression and patient responses to platinum-based chemotherapy, the correlation between eIF3a expression and 
lung cancer patients' survival is currently unknown. However, it has been observed previously that cervical and esophageal cancer patients with high eIF3a level had better relapse-free and overall survival than that with low eIF3a expression (24, 26). As mentioned above, cisplatin is one of the major chemotherapeutic drugs for both cervical and esophageal cancers. It is, thus, conceivable to speculate that high eIF3a expression level in lung cancer patients may contribute to better chemotherapy response and better survival of these patients.
Based on these observations, it is also tempting to speculate that eIF3a may serve as an independent prognostic marker predicting lung cancer patients' survival. Clearly, more studies are needed to further investigate the prognostic role of eIF3a.
The role of eIF3a in cellular response to cisplatin is likely via its regulation of expression of NER proteins such as XPA and XPC, which in turn affects DNA repair activities and cellular response to cisplatin. For example, it has been shown that XPC plays a crucial role in cellular response to cisplatin treatment (13, 35) . XPA level has also been shown to possibly contribute to platinum resistance in ovarian and lung cancers (9, 12) . Thus, up-or down-regulating expression of these proteins by altering eIF3a level likely results in changes in cellular NER activity and response to cisplatin. Previously, eIF3a has been shown to function as a regulator of translation of a subset of mRNAs including α-tubulin, ribonucleotide reductase M2 and p27 (19, 20) . The finding that altering eIF3a expression changed protein but not mRNA levels of XPA, XPC, RPA14, RPA32, RPA70, and Rad323B suggests that these mRNAs may also be under the translational control by eIF3a. DNA damage repair and ERCC1 has also been implicated as a prognosis marker of lung cancer patients (36, 37) . Interestingly, eIF3a has no effect on the expression of PCNA (Fig. 5) and XPF/ERCC1 (unpublished observation). Thus, XPF/ERCC1 and PCNA, unlike XPA, XPC, RPA, and Rad23B, are not under translational regulation by eIF3a. Currently, the reason for this difference in eIF3a regulation of NER proteins is unknown. However, these findings suggest that combination of the two independent prognosis factors eIF3a and ERCC1 may better predict survival of lung cancer patients, which clearly requires further investigation. These findings also suggest that translational regulation of XPA, XPC, RPA, and Rad23B by eIF3a is likely specific and NER proteins are not under a general upregulation pathway involving eIF3a. The mRNAs under eIF3a regulation may have a same element in their 5'-or 3'-UTRs, which can interact with eIF3a for reduced translation. We are currently testing this possibility. eIF3a also contributes to cellular sensitivity to anthracycline anticancer drugs such as doxorubicin. Although these drugs are known topoisomerase inhibitors and cause double strand DNA breaks, they also act to some degree via inducing DNA adduct formation (38) and NER was thought to be used to repair anthracycline-DNA adducts (39) . For example, it has been shown that reducing DNA repair by long-term XPC silencing led to an increased sensitivity to etoposide (40) . It is, thus, possible that the effect of eIF3a on cellular sensitivity to anthracyclines may also be via its regulation of NER protein expression. It is, however, also possible that eIF3a may regulate syntheses of proteins important for repairs of double strand DNA breaks. These possibilities will be tested in future studies. However, eIF3a appears to have no significant effect on cytotoxicity of non-DNAdamaging vinca alkaloid anti-cancer drugs that destabilize microtubules. This finding is surprising since we previously found that eIF3a up-regulates synthesis of α-tubulin (20) and knocking down eIF3a sensitized cells to G2/M arrest induced by nocodazole, a microtubule polymerization inhibitor (41) . The reason for this difference is currently unknown and warrants further studies of eIF3a on cellular response to different microtubule modulators.
In summary, we showed that eIF3a expression level correlates with responses of lung cancer patients to platinum-based chemotherapy. We also showed that eIF3a may regulate expression of NER proteins which in turn affects cellular NER activity and response to DNA damaging anti-cancer drugs such as cisplatin. It is tempting to speculate that eIF3a may also regulate the expression of proteins important for other mechanisms of DNA repair such as repair of double strand DNA breaks. eIF3a may represent a new prognostic marker predicting drug response and a novel mechanism of resistance to DNA-damaging anticancer drugs such as cisplatin.
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